Phase II Trial of Suberoylanilide Hydroxamic Acid (SAHA) [vorinostat] in Patients With Recurrent Glioblastoma.

Trial Profile

Phase II Trial of Suberoylanilide Hydroxamic Acid (SAHA) [vorinostat] in Patients With Recurrent Glioblastoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2013

At a glance

  • Drugs Vorinostat (Primary)
  • Indications Glioblastoma; Gliosarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Jul 2012 Actual end date 1 Mar 2010 added as reported by ClinicalTrials.gov record.(NCT01647100)
    • 19 Jul 2012 Actual end date 1 Mar 2010 added as reported by ClinicalTrials.gov record.(NCT01647100)
    • 16 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top